



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Muvalaplin

Item No. 39746

CAS Registry No.: 2565656-70-2
Formal Name: (α S, α' S, α'' S,3R,3'R,3''R)- α,α',α'' -[nitrilotris(methylene-3,1-phenylenemethylene)] tris-3-pyrrolidineacetic acid
Synonym: LY3473329
MF: C₄₂H₅₄N₄O₆
FW: 710.9
Purity: \geq 98%
Supplied as: A solid
Storage: -20°C
Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Muvalaplin is supplied as a solid. Aqueous solutions of muvalaplin can be prepared by directly dissolving the solid in aqueous buffers. Muvalaplin is slightly soluble (0.1-1 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

Muvalaplin is a trivalent binder of apolipoprotein A (ApoA).¹ It selectively binds to ApoA kringle domain IV type 8 (KIV8) over KIV2 (IC₅₀s = 22 and 3,900 nM, respectively). Muvalaplin also binds to rat plasminogen (K_d = <10 nM). It reduces the formation of lipoprotein A in a cell-free assay (IC₅₀ = 0.09 nM). Muvalaplin decreases plasma levels of lipoprotein A in mice expressing both human ApoA and human ApoB (LPA x ApoB100; ED₅₀ = 3 mg/kg). It reduces plasma levels of lipoprotein A in cynomolgus monkeys when administered at a dose of 100 mg/kg per day. Muvalaplin (31.6 mg/kg for four days) decreases *ex vivo* plasmin activity and plasminogen levels after administration in rats.

Reference

1. Diaz, N., Perez, C., Escribano, A.M., *et al.* Discovery of potent small-molecule inhibitors of lipoprotein(a) formation. *Nature* **629**(8013), 945-950 (2024).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/24/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM